Drugs / AdCD40L
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01455259 | Sep 2011 → Jan 2016 | melanoma | Uppsala University | Completed | No outcome recorded |
| Phase 1/2 | NCT00891748 | Nov 2006 → Oct 2009 | urinary bladder cancer | Uppsala University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdCD40L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01455259 ↗ |
| Action | Activate | “Stimulation of the CD40 pathway to initiate anti-tumor immunity is a promising alternative.” PMID 28427434 ↗ Apr 2017 |
| Route | Other | “is intratumorally injected/treatment.” NCT01455259 ↗ |
| Target | CD40LG | “Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter” NCT00891748 ↗ |